Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 5/20 | 0.40 |
| ▸ | RXRB | P28702 | 4/20 | 0.40 |
| ▸ | RXRG | P48443 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810484 | 0.81 | KMT2A (0.40) | MEN1KMT2AALDH1A1RXRAKDM4E | |
| SCHEMBL819226 | 0.78 | METAP2 (0.51) | ALDH1A1METAP2RXRARXRBRXRG | |
| SCHEMBL2787728 | 0.78 | SELL (0.47) | ALDH1A1METAP2RXRARXRBRXRG | |
| SCHEMBL13318318 | 0.77 | KDM4E (0.55) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL564223 | 0.77 | METAP2 (0.47) | ALDH1A1METAP2RXRARXRBRXRG | |
| SCHEMBL6419613 | 0.77 | RXRA (0.46) | ALDH1A1METAP2RXRARXRBRXRG | |
| SCHEMBL11741404 | 0.77 | CYP1A2 (0.50) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL87519 | 0.77 | CYP1A2 (0.57) | KMT2AALDH1A1RXRARXRBRXRG | |
| SCHEMBL11303591 | 0.76 | CYP1A2 (0.41) | MEN1KMT2AALDH1A1METAP2RXRA | |
| SCHEMBL720289 | 0.76 | METAP2 (0.46) | MEN1KMT2AALDH1A1METAP2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596564-B | diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORP. (KR) | 2016-05-04 | — | — | CN | disclosed |
| CN-103596564-A | Novel diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORP | 2014-02-19 | — | — | CN | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2061760-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | MEN1 1317/4885KMT2A 1619/4885ALDH1A1 453/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | MEN1 684/4885KMT2A 1240/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.